Promising treatment for dementia
Sodium selenate slows behavioural variant frontotemporal dementia -- second most common dementia in under 60s
- Date:
- May 5, 2022
- Source:
- Monash University
- Summary:
- A new study has found a promising new treatment for patients with behavioral variant fronto-temporal dementia, the second most common form of dementia in the under 60s -- resulting in a stabilizing of what would normally be escalating behavioral issues, and a slowing of brain shrinkage due to the disease. It is the second clinical trial to show that the drug, sodium selenate, may slow cognitive decline and neuro-degenerative damage that is the hallmark of many dementias including Alzheimer's Disease.
- Share:
A Monash University led study has found a promising new treatment for patients with behavioural variant frontotemporal dementia, the second most common form of dementia in the under 60s -- resulting in a stabilising of what would normally be escalating behavioural issues, and a slowing of brain shrinkage due to the disease. It is the second clinical trial to show that the drug, sodium selenate, may slow cognitive decline and neurodegenerative damage that is the hallmark of many dementias including Alzheimer's Disease.
Behavioural variant frontotemporal dementia (bvFTD) is a rapidly progressing destructive disease and can occur in people as young as 35 years of age. It is characterised by behavioural disturbances and personality changes and can be highly disruptive and distressing for both patients and their families. Currently there are no treatments or cures for bvFTD and typical survival is 5-7 years from diagnosis.
The Phase 1 trial run in conjunction with the Royal Melbourne Hospital, the only one in Australia targeting non-genetic bvFTD, and one of a handful worldwide, showed that the drug, sodium selenate is safe and well-tolerated in patients with bvFTD over a period of 12 months. Importantly, the majority of patients receiving sodium selenate showed no change in their cognitive or behavioural symptoms, and reduced rates of brain atrophy over the trial period. The results from the trial, led by Dr Lucy Vivash, from the Monash University's Department of Neuroscience, have just been published in the journal, Alzheimer's and Dementia: Translational Research and Clinical Interventions.
In almost half of the cases with bvFTD, the damage to the neurons in the brain is caused by the build-up of a protein called tau. This protein is a major target for research in the prevention and treatment of Alzheimer's and other dementias, as a way to reverse the neurodegeneration caused by this tau accumulation.
According to Dr Vivash, sodium selenate upregulates an enzyme in the brain that effectively breaks down the tau protein. "We have previously shown, in a Phase 2 trial, that sodium selenate given to patients with mild to moderate Alzheimer's Disease resulted in less neurodegeneration than in those who did not," she said. Importantly those patients in the trial with higher levels of selenium, a breakdown product of sodium selenate, in their bloodstream showed less cognitive decline.
The research group is now conducting a larger study at many hospitals across Australia and New Zealand to further test whether this drug is beneficial for patients with bvFTD.
Story Source:
Materials provided by Monash University. Note: Content may be edited for style and length.
Journal Reference:
- Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao‐Xin Li, Stuart McDonald, William T. O'Brien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis, Terence J. O'Brien. A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022; 8 (1) DOI: 10.1002/trc2.12299
Cite This Page: